Obesity overweight
Conditions
Interventions
Subjects will be asked to take two pills of nicotinamide riboside (250
mg/pill), or placebo, twice daily (two with breakfast and two with lunch, a
total of 4 pills/day), for 40 days.
Insulin sensitivity
Mitochondrial function
Nicotinamide riboside
Obesity
Sponsors
Medisch Universitair Ziekenhuis Maastricht
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Caucasian Males and postmenopausal females Aged 45-65 years at start of the study Body mass index (BMI) 27 * 35 kg/m2 Stable dietary habits (no weight loss or gain >5kg in the past 3 months) Sedentary lifestyle (not more than 2 hours of intensive exercise per week)
Exclusion criteria
Exclusion criteria: Type 2 diabetes Active diseases (cardiovascular, diabetes, liver, kidney, cancer or other) Contra-indication for MRI Participation in earlier research or medical examination that included PET/CT scanning Alcohol consumption of >2 servings per day Smoking in the past 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hepatic and whole body insulin sensitivity. | — |
Secondary
| Measure | Time frame |
|---|---|
| Muscle mitochondrial function. Ectopic lipid accumulation (intrahepatic and intramuscular). Brown adipose tissue activity. Cardiovascular risk parameters: cardiac energy status, 24h average systolic and diastolic blood pressure, plasma cholesterol levels (cholesterol, HDL, LDL, lathosterol), plasma vasodilatation markers (VCAM1, ICAM1, E-selectin, nitrite) and plasma markers of low grade inflammation (TNF*, interleukins). Whole-body energy expenditure. Body composition (fat mass and fat free mass). Acetylcarnitine levels. | — |
Countries
The Netherlands
Outcome results
None listed